Marathon Oil Announces $700 Million Northern Delaware

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
128
Marathon Oil Announces $700 Million Northern Delaware Acquisition

Houston, March 21, 2017 (GLOBE NEWSWIRE) -- Marathon Oil Corporation (NYSE: MRO) announced today the signing of a definitive agreement to acquire approximately 21,000 net surface acres largely in the Permian’s Northern Delaware basin of New Mexico from Black Mountain Oil & Gas and other private sellers for $700 million in cash, excluding closing adjustments.

“Today’s 21,000 acre bolt-on in the Northern Delaware is an excellent fit with the basin entry acquisition we announced earlier this month. The combined deals provide us more than 90,000 acres in the Permian, over 70,000 of which is concentrated in the Northern Delaware," Marathon Oil President and CEO Lee Tillman said. “While we expect to pursue additional trades and grassroots leasing, this bolt-on achieves the scale necessary for efficient long-term development in the basin.”

Black Mountain Acreage Highlights:

  • Up to 10 target benches within approximately 5,000 feet of stacked pay; base case assumes up to 6 target benches
  • Approximately 21,000 net acres with 20,000 net acres in the Northern Delaware basin; primary targets in world-class Wolfcamp and Bone Spring; roughly 400 boed of current production
  • Approximately 230 million BOE of risked resource with 440 gross Company operated locations
  • Approximately 550 million BOE of total resource potential with 950 total gross Company operated locations
  • High quality Northern Delaware inventory produces greater than 90% before-tax IRRs at $55 WTI flat and competes for capital allocation at top of Marathon Oil’s portfolio

Combined Permian Acreage Highlights:

  • Approximately 91,000 net Permian acres including 71,500 in the Northern Delaware
  • Implied total acreage cost of $18,400 per acre, or $23,400 per Northern Delaware acre, adjusting for existing production
  • Approximately 580 million BOE of risked resource with 1,070 gross Company operated locations
  • Approximately 1.45 billion BOE of total resource potential with 2,650 total gross Company operated locations from both tighter density and secondary targets
  • Further upside opportunities from 18,500 net acres in Northwest Shelf
  • One operated rig drilling with plans to add two more rigs mid-year

The Black Mountain acquisition is expected to close in second quarter 2017 with an effective date of March 1, 2017.

### 

Definitions: BOE: barrels of oil equivalent BOED: barrels of oil equivalent per day IRR: Internal rate of return WTI: West Texas intermediate crude

This release (and oral statements made regarding the subjects of this release)  contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements related to the Company’s 2017 capital program and the program objectives and flexibility; the proposed Permian basin acquisition and expected timing and projected impacts, including valuation, resource estimates, production estimates, asset quality and internal rates of return; the Company’s operational, financial and growth strategies, including drilling plans, rig count, asset development, planned projects, capital discipline, balance sheet protection, operational flexibility, cost reductions, efficiencies and non-core asset sales; and the Company’s ability to successfully effect those strategies and the expected timing thereof. While the Company believes that the assumptions concerning future events are reasonable, a number of factors could cause results to differ materially including, but not limited to: conditions in the oil and gas industry; capital available; drilling and operational risks, well production timing; availability of drilling rigs, materials and labor, including the costs associated therewith; the inability to obtain or delay in obtaining necessary government or third-party approvals and permits; the inability of any party to satisfy closing conditions with respect to the acquisition; and any non-performance by third parties of their contractual obligations. These forward-looking statements are also affected by the risk factors, forward-looking statements and challenges and uncertainties described in the Company's 2016 Annual Report on Form 10-K and other public filings and press releases, available at www.marathonoil.com. Except as required by law, the Company undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise.

Cautionary Note to Investors - The U.S. Securities and Exchange Commission (“SEC”) permits oil and gas companies, in their filings with the SEC, to disclose only proved, probable and possible reserves that meet the SEC’s definitions for such terms. Any resource estimates in this release, such as risked resource or total resource potential, that are not specifically designated as being estimates of proved, probable or possible reserves, may include other estimated resources that the SEC's guidelines prohibit us from including in filings with the SEC. Investors are urged to closely consider the disclosures in the Company’s periodic filings with the SEC, available at www.marathonoil.com or on the SEC’s website at www.sec.gov.

Media Relations Contact Lee Warren: 713-296-4103 Investor Relations Contact Zach Dailey: 713-296-4140

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CaliberMRI Revolutionizes Preclinical MRI with New Phantom

Updated Category News Views 107

CaliberMRI: Pioneers Shaping the Future of MRI Hot off the press, folks—CaliberMRI, known for setting the bar high in MRI standardization, has unleashed a new beast on the scene. Enter Model 340, a preclinical quantitative MRI phantom, ready to knock the socks off high-field systems. They’re talking 4.7T, 7T, and a jaw-dropping 9.4T compatibility here. This isn't just...

Continue Reading
LINE-X Seeks Veterans to Propel Franchise Growth

Updated Category News Views 55

If you've ever wondered about the intersection of military discipline and entrepreneurial spirit, LINE-X is handing veterans the keys, quite literally. With a nod to leathernecks and GIs, they're slashing their franchise fee by 25% for U.S. veterans aiming to trade sergeants' stripes for business clout. Franchising for Veterans: A Tailored Offer So, the word on the street...

Continue Reading
Peanuts and Diabetes: A Surprising Health Link

Updated Category News Views 68

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Continue Reading
Untapped $41B VA Loan Potential: Opportunities Missed

Updated Category News Views 106

VA Loans: Unused Potential Sits at $41 Billion Are you telling me we're leaving $41 billion just sitting on the table in the form of untapped VA loans? That's the figure staring us in the face according to Veterans United's latest analysis. It's not just about numbers; it's a head-scratcher given the growing VA loan market share, which hit 10% last year. Where's the...

Continue Reading
Key Insights Await in Sectra's Six-Month Report

Updated Category News Views 75

Sometimes the anticipation of a financial report presentation feels akin to waiting for a storm to pass or the sun to finally break through after what seems like endless rain. That’s the kind of vibe we're getting from Sectra's upcoming six-month report presentation. Slated for November 25, President Torbjörn Kronander and CFO Jessica Holmquist will be stepping up to...

Continue Reading
AI Shakes Up Boat Discovery: Traffic Soars for Leaders

Updated Category News Views 28

AI's Surge in the Boating World Well, look who’s riding the AI wave—it's our old friends at Boat Trader and YachtWorld, leaving the competition coughing in their slipstream. Similarweb data throws some cold, hard fish onto the deck, showing these two raking in over 17 times the AI-referred traffic compared to their closest peers. If you’re sniffing around for where...

Continue Reading
Accro's Vitiligo Trial Moves Fast with Fosun's Boost

Updated Category News Views 112

Launching into Vitiligo Treatment Trials I'll tell you, the biotech world isn't for the faint-hearted, especially when you're juggling hefty terms like 'TYK2/JAK1'. But here we are, watching Accro Bioscience and Fosun Pharma dive headlong into the vitiligo space with this Phase II/III trial of AC-201. They've bagged the IND clearance, and now the first patient is in the...

Continue Reading
CPC Biotech Debuts Quattroflow HTX Pump Drive

Updated Category News Views 51

Innovative Moves in Bioprocessing Let's get one thing clear right off the bat—CPC Biotech, part of Dover (NYSE: DOV), just sent a signal loud and clear with their new Quattroflow HTX all-in-one pump drive. With a slick touchscreen, flexible control options, and self-touting accuracy, this thing sounds like it's set to change the game for biopharmaceutical processing....

Continue Reading
AI Adoption Institute Targets ROI with Peer Circles

Updated Category News Views 73

Transforming AI from Cost to Profit Alright folks, we all know AI's the flashy tool everyone's jumping on like it's the latest tech bandwagon. But here’s the raw deal: most of these shiny AI investments ain't paying back a damn thing. Enter the AI Adoption Institute (AiAi)—a new player in Denver aiming to salvage this mess and make AI about actual returns. Peering...

Continue Reading
Bramshill Fund Takes Top Spot in 2026 Fund Awards

Updated Category News Views 78

Another Feather in Bramshill's Cap They've done it again, folks. The Bramshill Multi-Strategy Income Fund has just snagged the 40 Act Fund of the Year award at the 2026 Hedge Fund Performance Awards. This ain't just another plaque for the wall; it's a nod to some serious heavy lifting by the folks handling this beast of a portfolio. The award, dished out by With...

Continue Reading

Top 5 Most Recently Viewed Articles

Twilio's Q4 Results Spark Diverse Analyst Reactions

Updated Category News Views 232

Twilio Inc Fourth Quarter Overview Twilio Inc reported notable financial results for the fourth quarter, capturing the attention of several analysts within the market. The company’s performance has sparked diverse reactions, particularly regarding its future guidance and the evolving role of artificial intelligence within its operations. Market Response to Q4 Earnings...

Continue Reading
FHLBank Indianapolis Dividends for Second Quarter of 2025

Updated Category News Views 180

FHLBank Indianapolis Declares Second Quarter Dividends FHLBank Indianapolis recently announced its second quarter dividends for 2025, detailing robust financial strategies and growth, as reflected in the declared dividends on Class B-2 activity-based capital stock and Class B-1 non-activity-based stock. These dividends have been set at annualized rates of 9.50% and 4.50%,...

Continue Reading
Neurogen Biomarking Partners with Quanterix for Alzheimer's Testing

Updated Category News Views 255

Revolutionizing Alzheimer's Detection with Neurogen Biomarking Neurogen Biomarking is making significant strides in the healthcare landscape by introducing a pioneering blood test aimed at the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). This innovative approach leverages advanced biomarker technology developed by Quanterix Corporation,...

Continue Reading
Kepler Robotics Launches Innovative Humanoid Robot for Industries

Updated Category News Views 296

Revolutionizing Industries with the K2 Bumblebee Shanghai Kepler Robotics Co., Ltd has excitedly announced the commencement of mass production of its K2 "Bumblebee" model, confirming that the world's first commercially available hybrid-architecture humanoid robot is now shipping to eager customers. Milestone in Humanoid Robotics This significant development not only marks...

Continue Reading
Syntara Limited Reveals Groundbreaking Data in Myelofibrosis Trials

Updated Category News Views 259

Positive Interim Data from Syntara's Clinical Trials Syntara Limited, known for its innovative approach in drug development, has unveiled promising interim data concerning its ongoing Phase 2 study of SNT-5505. This clinical trial focuses on myelofibrosis, a complex bone marrow disorder that often leads to severe health complications. Details of the Clinical Trial The...

Continue Reading